Scientists at Gachon University and their collaborators investigated the neuroprotective effects of the GPR40 agonist TUG-469 in models of Parkinson’s disease (PD).
Dartmouth College has divulged fatty acid mimetics acting as free fatty acid FFA1 receptor (GPR40) and/or FFA4 receptor (GPR120) agonists reported to be useful for the treatment of obesity and type 2 diabetes.
At the ongoing ACS meeting in New Orleans, Rezubio Pharmaceuticals Co. Ltd. detailed the discovery and preclinical evaluation of novel small-molecule gut-restricted GPR40 agonists using membrane-anchored drug (MADD) design.
Liminal Biosciences Inc. has nominated a lead preclinical candidate, LMNL-6326, from its oxoeicosanoid receptor 1 (OXER1) antagonist program, targeting the treatment of eosinophil-driven diseases such as eosinophilic asthma and atopic dermatitis.
Evidence has suggested free fatty acid receptor 1 (FFAR1), also known as GPR40, as a promising therapeutic target in the treatment of type 2 diabetes, since its activation in pancreatic β cells promotes insulin secretion in a glucose concentration-dependent manner.
